Skip to content

Revenue at other companies

Clorox logo
CloroxCLX
$288M-0.3%
Revvity logo
RevvityRVTY
$408.23M-7.5%
CDW logo
CDWCDW
$3.12B+8.2%
IDEX logo
IDEXIEX
$299.46M-45.9%
NRG Energy logo
NRG EnergyNRG
$3.46B+19.6%
IonQ logo
IonQIONQ
$12.61M+625%

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's revenue?
BioMarin Pharmaceuticals (BMRN) reported revenue of $766.21M in Q1 2026.
How has BioMarin Pharmaceuticals's revenue changed year-over-year?
BioMarin Pharmaceuticals's revenue increased by 2.8% year-over-year, from $745.15M to $766.21M.
What is the long-term trend for BioMarin Pharmaceuticals's revenue?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's revenue has grown at a 14.9% compound annual growth rate (CAGR), from $1.85B to $3.22B.